BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28205056)

  • 41. Heart rate reduction with ivabradine in patients with acute decompensated systolic heart failure.
    Sargento L; Satendra M; Longo S; Lousada N; dos Reis RP
    Am J Cardiovasc Drugs; 2014 Jun; 14(3):229-35. PubMed ID: 24452599
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Health-related quality of life as measured by the EQ-5D in the prevention, screening and management of cervical disease: A systematic review.
    Ó Céilleachair A; O'Mahony JF; O'Connor M; O'Leary J; Normand C; Martin C; Sharp L
    Qual Life Res; 2017 Nov; 26(11):2885-2897. PubMed ID: 28653217
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ivabradine in heart failure--no paradigm SHIFT…yet.
    Teerlink JR
    Lancet; 2010 Sep; 376(9744):847-9. PubMed ID: 20801501
    [No Abstract]   [Full Text] [Related]  

  • 44. Predictors of self-reported health-related quality of life according to the EQ-5D-Y in chronically ill children and adolescents with asthma, diabetes, and juvenile arthritis: longitudinal results.
    Otto C; Barthel D; Klasen F; Nolte S; Rose M; Meyrose AK; Klein M; Thyen U; Ravens-Sieberer U
    Qual Life Res; 2018 Apr; 27(4):879-890. PubMed ID: 29189988
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
    Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
    PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term treatment with ivabradine over 12months in patients with chronic heart failure in clinical practice: Effect on symptoms, quality of life and hospitalizations.
    Zugck C; Störk S; Stöckl G;
    Int J Cardiol; 2017 Aug; 240():258-264. PubMed ID: 28408104
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer.
    Skaltsa K; Longworth L; Ivanescu C; Phung D; Holmstrom S
    Value Health; 2014 Mar; 17(2):238-44. PubMed ID: 24636382
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors influencing health-related quality of life in patients with Type 1 diabetes.
    Raymakers AJN; Gillespie P; O'Hara MC; Griffin MD; Dinneen SF
    Health Qual Life Outcomes; 2018 Feb; 16(1):27. PubMed ID: 29394942
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Investigating the association between medication adherence and health-related quality of life in COPD: Methodological challenges when using a proxy measure of adherence.
    Boland MR; van Boven JF; Kruis AL; Chavannes NH; van der Molen T; Goossens LM; Rutten-van Mölken MP
    Respir Med; 2016 Jan; 110():34-45. PubMed ID: 26639189
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Addressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of Ivabradine.
    Pereira-Barretto AC
    Am J Cardiovasc Drugs; 2016 Apr; 16(2):93-101. PubMed ID: 26817946
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.
    Cella D; Grünwald V; Nathan P; Doan J; Dastani H; Taylor F; Bennett B; DeRosa M; Berry S; Broglio K; Berghorn E; Motzer RJ
    Lancet Oncol; 2016 Jul; 17(7):994-1003. PubMed ID: 27283863
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial.
    Ambrosy AP; Khan H; Udelson JE; Mentz RJ; Chioncel O; Greene SJ; Vaduganathan M; Subacuis HP; Konstam MA; Swedberg K; Zannad F; Maggioni AP; Gheorghiade M; Butler J
    Circ Heart Fail; 2016 May; 9(5):. PubMed ID: 27140204
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modeling Monthly Migraine-Day Distributions Using Longitudinal Regression Models and Linking Quality of Life to Inform Cost-Effectiveness Analysis: A Case Study of Fremanezumab in Japanese-Korean Migraine Patients.
    Wang X; Yamato K; Kojima Y; Paris JJ; Peterse EFP; Simons MJHG; Bennison C
    Pharmacoeconomics; 2023 Oct; 41(10):1263-1274. PubMed ID: 37318748
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association between disease activity and quality of life in ulcerative colitis: Results from the CRONICA-UC study.
    Panés J; Domènech E; Aguas Peris M; Nos P; Riestra S; Juliá de Páramo B; Cea-Calvo L; Romero C; Marín-Jiménez I
    J Gastroenterol Hepatol; 2017 Nov; 32(11):1818-1824. PubMed ID: 28370253
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Health-related quality of life in HIV/AIDS patients on antiretroviral therapy at a tertiary care facility in Zimbabwe.
    Mafirakureva N; Dzingirai B; Postma MJ; van Hulst M; Khoza S
    AIDS Care; 2016 Jul; 28(7):904-12. PubMed ID: 27098289
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: systematic reviews of clinical effectiveness and cost-effectiveness.
    Pickett K; Loveman E; Kalita N; Frampton GK; Jones J
    Health Technol Assess; 2015 Oct; 19(86):1-176, v-vi. PubMed ID: 26502807
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
    Bocchi EA; Böhm M; Borer JS; Ford I; Komajda M; Swedberg K; Tavazzi L;
    Cardiology; 2015; 131(4):218-24. PubMed ID: 25968495
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief.
    Pennant M; Orlando R; Barton P; Bayliss S; Routh K; Meads C
    Health Technol Assess; 2011 May; 15 Suppl 1():43-50. PubMed ID: 21609652
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT.
    Komajda M; Böhm M; Borer JS; Ford I; Robertson M; Manolis AJ; Tavazzi L; Swedberg K;
    Eur J Heart Fail; 2014 Jul; 16(7):810-6. PubMed ID: 24961493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.